Current Journal of Neurology

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Peer Review Process

Journal Metrics

News

Publication Ethics and Malpractice Statement

Anticoagulation in the management of septic cavernous sinus thrombosis secondary to rhino-orbito-cerebral mucormycosis: A retrospective real-world experience

Articles in Press

Document Type : Original Article

Authors

1 Neurology Ward, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

2 Iranian Center of Neurological Research, Neuroscience Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran

3 School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: COVID-19 was associated with an increased number of patients with mucormycosis (MCR), followed by septic cavernous sinus thrombosis (SCST). We evaluated the association between anticoagulation (AC) and mortality/morbidity of COVID-19-associated MCR (CAM)-induced SCST.
Methods: In this retrospective study, neurological sequelae, functional outcomes, and in-hospital mortality were compared between AC receivers and non-receivers. In addition, the association between AC and survivability was examined.
Results: Twenty-nine patients (17 male; mean age: 51.27 years) with CAM-induced SCST were included in the study. 
The median intervals between COVID-19 and MCR, and COVID-19 and SCST were 19 and 27 days, respectively. Among AC recipients, the interval between SCST and AC initiation was 18 days, with an AC duration of 37 days. Baseline and management-related characteristics were comparable between AC recipients and non-recipients (P > 0.050). AC receivers (n = 15) and non-receivers (n = 14) did not significantly differ in terms of the proportion of sequelae (6/15 vs. 5/14; P = 1.000), complete recovery (2/15 vs. 4/14; P = 0.687), and in-hospital mortality (3/15 vs. 3/14; P > 0.999). Nevertheless, AC recipients had a longer hospital stay (72.0 vs. 35.5; P = 0.016). AC-related characteristics (AC receiving, type, early initiation, and duration) were not significantly different between survivors and non-survivors, or between recovered and disabled patients.
Conclusion: In our study, CAM-induced SCST in-hospital mortality/morbidity did not differ between AC receivers and non-receivers. AC characteristics were not different between survivors and non-survivors, or recovered and disabled patients. However, the small sample size may have limited the ability to detect significant differences, leading to inconclusive results.

Keywords

References
  1. Caranfa JT, Yoon MK. Septic cavernous sinus thrombosis: A review. Surv Ophthalmol 2021; 66(6): 1021-30.
  2. Kojan S, Al-Jumah M. Infection related cerebral venous thrombosis. J Pak Med Assoc 2006; 56(11): 494-7.
  3. Southwick F. Septic Dural Sinus Thrombosis [Online]. [cited 2020 Nov 20]; Available from: URL: https://www.uptodate.com/contents/septic-dural-sinus-thrombosis#:~:text=Septic%20dural%20sinus%20thrombosis%20is,during%20his%20or%20her%20career
  4. Jacob MS, Gunasekaran K, Miraclin AT, Sadiq M, Kumar CV, Oommen A, et al. Clinical profile and outcome of patients with cerebral venous thrombosis secondary to bacterial infections. Ann Indian Acad Neurol 2020; 23(4): 477-81.
  5. Weerasinghe D, Lueck CJ. Septic cavernous sinus thrombosis: Case report and review of the literature. Neuroophthalmology 2016; 40(6): 263-76.
  6. World Health Organization. WHO COVID-19 dashboard [Online]. [cited 2022 Feb 28]; Available from: URL: https://data.who.int
  7. Zali A, Khodadoost M, Gholamzadeh S, Janbazi S, Piri H, Taraghikhah N, et al. Mortality among hospitalized COVID-19 patients during surges of SARS-CoV-2 alpha (B.1.1.7) and delta (B.1.617.2) variants. Sci Rep 2022; 12(1): 18918.
  8. Jameie M, Safarian NM, Mansouri P, Jalali A, Aghajani F, Lotfi-Tokaldany M, et al. The impact of the COVID-19 pandemic on hospitalization rates due to prosthetic valve thrombosis. J Tehran Heart Cent 2023; 18(2): 136-41.
  9. Soheili A, Khani S, Montazeri S, Shayegh A, Haji Miragha M, Jameie MS, et al. COVID-19 and acute kidney injury presentation; stages and prognosis. J Prev Epidemiol 2021; 6(1): e15.
  10. Majidi F, Mohagheghi Dare Ranj A, Jameie M, Jameie M, Mansouri P, Varpaei HA, et al. The relationship between cardiological parameters and PCR in patients with coronavirus infection: A cross-sectional study. Medicine (Baltimore) 2022; 101(50): e31935.
  11. Wang C, Tee M, Roy AE, Fardin MA, Srichokchatchawan W, Habib HA, et al. The impact of COVID-19 pandemic on physical and mental health of Asians: A study of seven middle-income countries in Asia. PLoS One 2021; 16(2): e0246824.
  12. Duden GS, Reiter J, Paswerg A, Weibelzahl S. Mental health of healthcare professionals during the ongoing COVID-19 pandemic: A comparative investigation from the first and second pandemic years. BMJ Open 2023; 13(3): e067244.
  13. Borhany H, Golbabaei S, Jameie M, Borhani K. Moral decision-making in healthcare and medical professions during the COVID-19 pandemic. Trends in Psychol 2023; 31(1): 210-30.
  14. Rafati A, Pasebani Y, Jameie M, Yang Y, Jameie M, Ilkhani S, et al. Association of SARS-CoV-2 vaccination or infection with bell palsy: A systematic review and meta-analysis. JAMA Otolaryngol Head Neck Surg 2023; 149(6): 493-504.
  15. Harirchian MH, Ghabaee M, Sarraf P, Ranji-Burachaloo S, Agah E, Mousavi SV, et al. Nervous system involvement in hospitalized patients with COVID-19: Clinical and laboratory associations with poorer outcomes. Infect Dis Clin Pract 2023; 32(1): e1332.
  16. Jameie M, Togha M, Azizmohammad LM, Jafari E, Yazdan PM, Hemmati N, et al. Characteristics of headaches attributed to SARS-CoV-2 vaccination and factors associated with its frequency and prolongation: A cross-sectional cohort study. Front Neurol 2023; 14: 1214501.
  17. Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: A tale of two pathogens. Indian J Ophthalmol 2021; 69(2): 244-52.
  18. Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol 2021; 69(4): 1002-4.
  19. Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus 2020; 12(9): e10726.
  20. Joshi S, Telang R, Tambe M, Havaldar R, Sane M, Shaikh A, et al. Outbreak of mucormycosis in coronavirus disease patients, Pune, India. Emerg Infect Dis 2022; 28(1): 1-8.
  21. Garg S, Masheshwari D, Bhushan B, Sardana V, Jain RK. Covid-19 and mucormycosis superinfection: prospective, obsevational study in a single center. Ann Indian Acad Neurol 2022; 25(3): 441-8.
  22. Mahalaxmi I, Jayaramayya K, Venkatesan D, Subramaniam MD, Renu K, Vijayakumar P, et al. Mucormycosis: An opportunistic pathogen during COVID-19. Environ Res 2021; 201: 111643.
  23. Rocha ICN, Hasan MM, Goyal S, Patel T, Jain S, Ghosh A, et al. COVID-19 and mucormycosis syndemic: Double health threat to a collapsing healthcare system in India. Trop Med Int Health 2021; 26(9): 1016-8.
  24. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021; 15(4): 102146.
  25. Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol 2021; 69(7): 1670-92.
  26. Avatef FM, Rezaei L, Javadirad E, Iranfar K, Khosravi A, Amini SJ, et al. Increased incidence of rhino-orbital mucormycosis in an educational therapeutic hospital during the COVID-19 pandemic in western Iran: An observational study. Mycoses 2021; 64(11): 1366-77.
  27. Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, et al. Mucormycosis in patients with COVID-19: A cross-sectional descriptive multicentre study from Iran. Mycoses 2021; 64(10): 1238-52.
  28. Kulkarni R, Pujari S. COVID-19-associated mucormycosis: What neurologists should know? Ann Indian Acad Neurol 2022; 25(3): 330-1.
  29. Cox GM. Mucormycosis (zygomycosis) [Online]. [cited 2023 Jan 22]; Available from: URL: https://www.uptodate.com/contents/mucormycosis-zygomycosis?search=Mucormycosis%20(zygomycosis)&source=search_result&selectedTitle=1~70&usage_type=default&display_rank=1
  30. Khacha A, Bouchal S, Ettabyaoui A, Haloua M, Lamrani YA, Boubbou M, et al. Cavernous sinus thrombosis in a COVID-19 patient: A case report. Radiol Case Rep 2021; 16(3): 480-2.
  31. Padma Srivastava MV, Vishnu VY, Pandit AK. Mucormycosis epidemic and stroke in India during the COVID-19 pandemic. Stroke 2021; 52(10): e622-e623.
  32. Nehara HR, Puri I, Singhal V, Ih S, Bishnoi BR, Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: Case series from the north-western part of India. Indian J Med Microbiol 2021; 39(3): 380-3.
  33. Dubey S, Mukherjee D, Sarkar P, Mukhopadhyay P, Barman D, Bandopadhyay M, et al. COVID-19 associated rhino-orbital-cerebral mucormycosis: An observational study from Eastern India, with special emphasis on neurological spectrum. Diabetes Metab Syndr 2021; 15(5): 102267.
  34. Bhatia K, Jones NS. Septic cavernous sinus thrombosis secondary to sinusitis: are anticoagulants indicated? A review of the literature. J Laryngol Otol 2002; 116(9): 667-76.
  35. Desa V, Green R. Cavernous sinus thrombosis: Current therapy. J Oral Maxillofac Surg 2012; 70(9): 2085-91.
  36. Southwick FS, Richardson EP, Swartz MN. Septic thrombosis of the dural venous sinuses. Medicine (Baltimore) 1986; 65(2): 82-106.
  37. Pirkey WP. Thrombosis of the cavernous sinus. Arch Otolaryngol (1925) 1950; 51(6): 917-24.
  38. Sheikhi F, Yousefian N, Tehranipoor P, Kowsari Z. Estimation of the basic reproduction number of Alpha and Delta variants of COVID-19 pandemic in Iran. PLoS One 2022; 17(5): e0265489.
  39. World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013; 310(20): 2191-4.
  40. Yu IT, Tse SL. Workshop 3--source of bias in case series, patient cohorts, and randomised controlled trials. Hong Kong Med J 2011; 17(6): 478-9.
  41. Caliendo AM, Hanson KE. COVID-19: Diagnosis [Online]. [cited 2023 Feb 6]; Available from: URL: https://www.uptodate.com/contents/covid-19-diagnosis
  42. Chakravarty J, Gupta MK, Tilak R, Kumar R, Maurya RP, Kumar N, et al. COVID-19-associated Mucormycosis: A clinico-epidemiological study. J Diabetes Complications 2022; 36(9): 108284.
  43. Quinn TJ, Dawson J, Walters MR, Lees KR. Functional outcome measures in contemporary stroke trials. Int J Stroke 2009; 4(3): 200-5.
  44. Levine SR, Twyman RE, Gilman S. The role of anticoagulation in cavernous sinus thrombosis. Neurology 1988; 38(4): 517-22.
  45. National Institutes of Health. Clinical Spectrum of SARS-CoV-2 Infection [Online]. [cited 2022 Jun 6]; Available from: URL: https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
  46. Munjal M, Khurana AS. Fungal infections and cavernous sinus thrombosis. Indian J Otolaryngol Head Neck Surg 2004; 56(3): 235-7.
  47. Li DM, Shang PP, Zhu L, De Hoog GS. Rhino-orbital-cerebral mycosis and cavernous thrombosis. Eur J Inflamm 2014; 12(1): 1-10.
  48. Gelston CD, Durairaj VD, Simoes EA. Rhino-orbital mucormycosis causing cavernous sinus and internal carotid thrombosis treated with posaconazole. Arch Ophthalmol 2007; 125(6): 848-9.
  49. Kulkarni R, Misra UK, Meshram C, Kochar D, Modi M, Vishnu VY, et al. Epidemic of mucormycosis in COVID-19 pandemic: A position paper. Ann Indian Acad Neurol 2022; 25(1): 7-10.
  50. Yadav S, Bs N, Ak S. Clinical profile of central nervous system involvement in patients with rhino orbital cerebral mucormycosis. J Assoc Physicians India 2022; 70(4): 11-2.
  51. van der Poel NA, Mourits MP, de Win MML, Coutinho JM, Dikkers FG. Prognosis of septic cavernous sinus thrombosis remarkably improved: A case series of 12 patients and literature review. Eur Arch Otorhinolaryngol 2018; 275(9): 2387-95.
  52. Paybast S, Mohamadian R, Emami A, Jameie M, Shahrab F, Zamani F, et al. Safety and efficacy of endovascular thrombolysis in patients with acute cerebral venous sinus thrombosis: A systematic review. Interv Neuroradiol 2022; 15910199221143418. [Online ahead of print].
  53. Wang YH, Chen PY, Ting PJ, Huang FL. A review of eight cases of cavernous sinus thrombosis secondary to sphenoid sinusitis, including a12-year-old girl at the present department. Infect Dis (Lond) 2017; 49(9): 641-6.
  54. Rebelo J, Nayan S, Choong K, Fulford M, Chan A, Sommer DD. To anticoagulate? Controversy in the management of thrombotic complications of head & neck infections. Int J Pediatr Otorhinolaryngol 2016; 88: 129-35.
  55. Funamura JL, Nguyen AT, Diaz RC. Otogenic lateral sinus thrombosis: Case series and controversies. Int J Pediatr Otorhinolaryngol 2014; 78(5): 866-70.
  56. Shah UK, Jubelirer TF, Fish JD, Elden LM. A caution regarding the use of low-molecular weight heparin in pediatric otogenic lateral sinus thrombosis. Int J Pediatr Otorhinolaryngol 2007; 71(2): 347-51.
Current Journal of Neurology

Articles in Press, Accepted Manuscript
Available Online from 16 January 2024
Files
Share
How to cite
Statistics